Aniello Sorrentino - Bumrungrad Hospital Chief Strategist
BZ7A Stock | EUR 5.60 0.20 3.45% |
Insider
Aniello Sorrentino is Chief Strategist of Bumrungrad Hospital Public
Age | 76 |
Phone | 66 2 066 8888 |
Web | https://www.bumrungrad.com |
Bumrungrad Hospital Management Efficiency
The company has return on total asset (ROA) of 0.1665 % which means that it generated a profit of $0.1665 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2646 %, meaning that it generated $0.2646 on every $100 dollars invested by stockholders. Bumrungrad Hospital's management efficiency ratios could be used to measure how well Bumrungrad Hospital manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Steven Humphreys | Identiv | 62 | |
Patric Erlandsson | SIVERS SEMICONDUCTORS AB | 51 | |
Mike Taylor | Identiv | N/A | |
Erik Fallstrom | SIVERS SEMICONDUCTORS AB | 56 | |
Bjorn Norrbom | SIVERS SEMICONDUCTORS AB | 72 | |
Erik Wiklund | SIVERS SEMICONDUCTORS AB | 49 | |
Norman Fitzgerald | NMI Holdings | 56 | |
Martyn Roberts | Ramsay Health Care | 55 | |
Manfred Mueller | Identiv | 53 | |
Doug Meagher | Ramsay Health Care | N/A | |
JeanJacques Henchoz | Talanx AG | 59 | |
Allison Miller | NMI Holdings | N/A | |
Kah Hong | Ramsay Health Care | 50 | |
Steve Dunlap | Identiv | N/A | |
Sven Pettersson | SIVERS SEMICONDUCTORS AB | 60 | |
Andrew Wearne | Ramsay Health Care | N/A | |
James Devens | Superior Plus Corp | N/A | |
CCLP CMA | Superior Plus Corp | 62 | |
Larry Cordell | Origin Agritech | 56 | |
Jan Wicke | Talanx AG | 55 | |
Colleen Harris | Ramsay Health Care | 54 |
Management Performance
Return On Equity | 0.26 | |||
Return On Asset | 0.17 |
Bumrungrad Hospital Leadership Team
Elected by the shareholders, the Bumrungrad Hospital's board of directors comprises two types of representatives: Bumrungrad Hospital inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bumrungrad. The board's role is to monitor Bumrungrad Hospital's management team and ensure that shareholders' interests are well served. Bumrungrad Hospital's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bumrungrad Hospital's outside directors are responsible for providing unbiased perspectives on the board's policies.
Daniel Kastner, Chief IR | ||
Artirat Charukitpipat, Chief Officer | ||
Rangsima Thongdee, Head Audit | ||
Aniello Sorrentino, Chief Strategist | ||
David FACHE, Chief Officer | ||
Oraphan Buamuang, Chief Officer | ||
Jeremy Ford, Laboratory Hospital | ||
Supawan Sirinuntawit, Accounting Mang | ||
Linda Lisahapanya, MD Pres | ||
Tanee Maneenut, Chief Officer |
Bumrungrad Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bumrungrad Hospital a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.26 | |||
Return On Asset | 0.17 | |||
Profit Margin | 0.24 % | |||
Operating Margin | 0.29 % | |||
Current Valuation | 4.37 B | |||
Shares Owned By Institutions | 7.43 % | |||
Price To Earning | 29.56 X | |||
Price To Book | 9.12 X | |||
Price To Sales | 0.25 X | |||
Revenue | 20.72 B |
Currently Active Assets on Macroaxis
Other Information on Investing in Bumrungrad Stock
Bumrungrad Hospital financial ratios help investors to determine whether Bumrungrad Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bumrungrad with respect to the benefits of owning Bumrungrad Hospital security.